Evaluation of Axillary Staging in Breast Cancer Patients After Neoadjuvant Chemotherapy: A Prognostic Study Comparing Pathological Node Staging and Lymph Node Ratio Metrics in a Series of 169 Cases - Scorecard - MDSpire
Advertisement
Evaluation of Axillary Staging in Breast Cancer Patients After Neoadjuvant Chemotherapy: A Prognostic Study Comparing Pathological Node Staging and Lymph Node Ratio Metrics in a Series of 169 Cases
Clinical Scorecard: Evaluation of Axillary Staging in Breast Cancer Patients After Neoadjuvant Chemotherapy: A Prognostic Study Comparing Pathological Node Staging and Lymph Node Ratio Metrics in a Series of 169 Cases
At a Glance
Category
Detail
Condition
Key Mechanisms
Target Population
Breast cancer patients who received neoadjuvant chemotherapy, specifically those undergoing axillary staging.
Care Setting
Key Highlights
Highlight the prognostic implications of the nine axillary nodal variables.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Regular follow-up for breast cancer-free survival (BCFS) post-surgery, ideally every 3-6 months for the first 2 years.
Risks
Patient & Prescribing Data
169 breast cancer patients who underwent neoadjuvant chemotherapy.
Data on NAC delivery sessions and adjuvant therapies were collected.
Clinical Best Practices
Detail methods for integrating emerging biological markers with clinical staging systems.
